ESR1 and breast carcinoma: We selected three PIK3CA-mutant (MCF7, EFM-19, and T-47D) and two PIK3CA-wildtype PTEN-lost (ZR-75-1 and CAMA-1) ER+ breast cancer cell lines for the study.